Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 4 of 13.
Jun 2021
28 Jun · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone auditors report not submitted. The response of the Company is awaited.28 Jun · Legal
Clarification - Financial Results26 Jun · Board meeting
May 2021
Apr 2021
Mar 2021
18 Mar · Legal
The exchange asked on 17 Mar 2021
17 Mar · Significant movement in price has been observed in Bafna Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Price movement
Feb 2021
12 Feb · Board meeting
Jan 2021
Dec 2020
7 Dec · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated Financial Results not submitted The response of the Company is awaited.7 Dec · Legal
Clarification - Financial Results
Nov 2020
12 Nov · Board meeting
Sep 2020
23 Sep · Legal
The exchange asked on 22 Sep 2020
22 Sep · Significant movement in price has been observed in Bafna Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Price movement10 Sep · Board meeting
Aug 2020
Jul 2020
14 Jul · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.14 Jul · Legal
Clarification - Financial Results
Jun 2020
25 Jun · Board meeting
Mar 2020
16 Mar
File name: “updatetostockexchange16thmar2020”
Feb 2020
13 Feb · Board meeting